

Prostate Cancer Metastatic Prostate Cancer

Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer

Trial Status
Active, not recruiting

Trial Runs In
26 Countries

Trial Identifier
NCT03072238 CO39303

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ipatasertib plus abiraterone and prednisone/prednisolone compared with placebo plus abiraterone and prednisone/prednisolone in participants with metastatic castrate-resistant prostate cancer (mCRPC).

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT03072238 CO39303
Trial Identifiers

Eligibility Criteria:

Gender
Male

Age
≥ 18 Years

Healthy Volunteers
No